10x Genomics, Inc. Class A Common Stock

10x Genomics, Inc. Class A Common Stock

Compare this stock

TXG Stock Report Card

$

VolatilityTechnicalsProfitPerformanceEarnings

37%

Performance

Score:

100/100

TXG returned -0.42% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.

Technicals

Score:

50/100

TXG receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

Score:

10/100

TXG has missed earnings 8 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 20 quarters, TXG has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

55/100

TXG has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

10x Genomics, Inc. Class A Common Stock Summary

Nasdaq / TXG
Healthcare
Medical - Healthcare Information Services
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.